LC-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
(More reactive lithium (SEP −3.04 V) is used for anodes in lithium batteries). Powdered zinc is used in this way in alkaline batteries and the case (which also serves as the anode) of zinc–carbon batteries is formed from sheet zinc. There are also efforts to use zinc as anode material in secondary cells with a comparable cell chemistry, for example by advanced electrolytes. Zinc is used as the anode or fuel of the zinc–air battery/fuel cell. The zinc-cerium redox flow battery also relies on a zinc-based negative half-cell.
In the late 1940s, the geopolitics of the Eastern Bloc countries under Soviet predominance featured an official-and-personal style of socialist diplomacy that failed Stalin and Tito when Tito refused to subordinating Yugoslavia to the Soviet Union. In 1948, circumstance and cultural personality aggravated the matter into the Yugoslav–Soviet split (1948–1955) that resulted from Tito's rejection of Stalin's demand to subordinate the Federal People's Republic of Yugoslavia to the geopolitical agenda (economic and military) of the Soviet Union, i.e. Tito at Stalin's disposal. Stalin punished Tito's refusal by denouncing him as an ideological revisionist of Marxism–Leninism; by denouncing Yugoslavia's practice of Titoism as socialism deviated from the cause of world communism; and by expelling the Communist Party of Yugoslavia from the Communist Information Bureau (Cominform). The break from the Eastern Bloc allowed the development of a socialism with Yugoslav characteristics which allowed doing business with the capitalist West to develop the socialist economy and the establishment of Yugoslavia's diplomatic and commercial relations with countries of the Eastern Bloc and the Western Bloc. Yugoslavia's international relations matured into the Non-Aligned Movement (1961) of countries without political allegiance to any power bloc. At the death of Stalin in 1953, Nikita Khrushchev became leader of the Soviet Union and of the Communist Party of the Soviet Union and then consolidated an anti-Stalinist government.
The unaltered proteins were then treated with recombinant FGE from Mycobacterium tuberculosis in vitro in which the aldehyde group was successfully installed at the glycosylation site of Fc (Fig. 3A). Next, the introduction of N-acetylglucoseamine (GlcNAc) to the aldehyde tagged proteins via oxime formation was carried out through the treatment with aminooxy GlcNAc (AO-GlcNAc) (Fig. 3B). The conjugation was confirmed by liquid chromatography-electrospray ionisation-mass spectrometry (LC-ESI-MS) and lectin blot with the GlcNAc-binding wheat germ agglutinin attached to AlexaFluor 647. Having successfully introduced GlcNAc, the monomer was extended with a glycan structure containing GlcNAc, mannose (Man) and galactose (Gal) (Fig. 3C). A mutant endoglycosidase EndoS (EndoS-D233Q) was utilised as it is highly specific for IgG Fc N-linked GlcNAc residues and does not elongate Asn-GlcNAc sites on other proteins or on denatured IgGs. Product formation was again monitored by LC-ESI-MS and lectin blot probing, with the sialic acid-binding sambucus nigra agglutinin attached to fluorescein isothiocyanate. A successful chemical glycosylation of the Fc IgG fragment was achieved which resembles the natural occurring glycosylation pattern. The study discussed above focused on the IgG antibody, however, the application of the aldehyde tag for glycan conjugation could potentially be extended to other proteins.
On April 11, 2018, Starbucks began operations in Uruguay, with a location in the Montevideo Shopping mall. The company announced that it planned to open up approximately 12 cafes in the country. In August 2019, a franchised location opened in the Cayman Islands. In October 2019, a franchised location opened in the Turks and Caicos Islands. On April 25, 2023, Starbucks commenced operations in Guyana. On April 29, 2024, Starbucks announced its official entry to Ecuador and Honduras in mid-year and late 2024, respectively. On August 14, 2024, Starbucks commenced operations in Ecuador, with its first location in the country at Scala Shopping Mall in Quito. The company announced the plans of opening four more cafes in the capital city until the end of 2025. In July 2026, Starbucks opened its first location in Guayaquil, and now has 10 stores across the country.
Sources: en.wikipedia.org
This is a list of investigational acne drugs, or drugs that are currently under development for clinical use in the treatment of acne but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
In people with severe valvular disease, however, short-term risks of cardiovascular compromise after intramuscular injections may outweigh the benefits, and oral therapy may be considered instead of IM injections in this subset of patients. Diseases of the aortic root can cause chronic aortic regurgitation. These diseases include syphilitic aortitis, Behçet's disease, and reactive arthritis.
l-Histidine is an essential amino acid that is not synthesized de novo in humans. Humans and other animals must ingest histidine or histidine-containing proteins. The biosynthesis of histidine has been widely studied in prokaryotes such as E. coli. Histidine synthesis in E. coli involves eight gene products (His1, 2, 3, 4, 5, 6, 7, and 8) and it occurs in ten steps. This is possible because a single gene product has the ability to catalyze more than one reaction. For example, as shown in the pathway, His4 catalyzes four different steps in the pathway. Histidine is synthesized from phosphoribosyl pyrophosphate (PRPP), which is made from ribose-5-phosphate by ribose-phosphate diphosphokinase in the pentose phosphate pathway. The first reaction of histidine biosynthesis is the condensation of PRPP and adenosine triphosphate (ATP) by the enzyme ATP-phosphoribosyl transferase. ATP-phosphoribosyl transferase is indicated by His1 in the image. His4 gene product then hydrolyzes the product of the condensation, phosphoribosyl-ATP, producing phosphoribosyl-AMP (PRAMP), which is an irreversible step. His4 then catalyzes the formation of phosphoribosylformiminoAICAR-phosphate, which is then converted to phosphoribulosylformimino-AICAR-P by the His6 gene product. His7 splits phosphoribulosylformimino-AICAR-P to form d-erythro-imidazole-glycerol-phosphate. After, His3 forms imidazole acetol-phosphate releasing water. His5 then makes l-histidinol-phosphate, which is then hydrolyzed by His2 making histidinol.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.